ENO1 has been found to induce autoantibody production in patients with cholangiocarcinoma, breast tumor, head and neck tumor, leukemia, lung tumor, pancreatic tumor, and melanoma (26, 28, 50–52). This evidence concerns the gene ENO1 and melanoma.